Lung Cancer
Volume 72, Issue 1 , Pages 59-63 , April 2011

Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)

  • D. Galetta

      Affiliations

    • Department of Medical Oncology, “Giovanni Paolo II” Oncology Institute, Via Hanehman 10, 7016 Bari, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 080 5555236; fax: +39 080 5555263.
    • ,
  • V. Gebbia

      Affiliations

    • Medical Oncology Division,” La Maddalena” Hospital, Palermo, Italy
    • ,
  • N. Silvestris

      Affiliations

    • Department of Medical Oncology, “Giovanni Paolo II” Oncology Institute, Via Hanehman 10, 7016 Bari, Italy
    • ,
  • F. Ferraù

      Affiliations

    • Medical Oncology Division, Taormina Hospital, Catania, Italy
    • ,
  • F. Carrozza

      Affiliations

    • Medical Oncology Division, Cardarelli Hospital, Campobasso, Italy
    • ,
  • S. Cigolari

      Affiliations

    • Medical Oncology Division, San Giovanni Hospital, Salerno, Italy
    • ,
  • P. Russo

      Affiliations

    • Medical Oncology Division,” La Maddalena” Hospital, Palermo, Italy
    • ,
  • F. Calista

      Affiliations

    • Departement of Medical Oncology, Catholic University, Campobasso, Italy
    • ,
  • V. Adamo

      Affiliations

    • Medical Oncology University of Messina, Messina, Italy
    • ,
  • G. Colucci

      Affiliations

    • Department of Medical Oncology, “Giovanni Paolo II” Oncology Institute, Via Hanehman 10, 7016 Bari, Italy

Received 25 January 2010 ,Revised 26 July 2010 ,Accepted 29 July 2010.

References 

  1. Azzoli CG, Baker S, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27:6251–6266
  2. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005;75:5–14
  3. Lagerwaard F, Levendag P, Nowak P, Eijkenboom W, Hanssens P, Schmitz P. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43:795–803
  4. Tsao MN, Lloyd N, Wong R, Chow E, Rakovitch E, Laperriere N. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev. 2006;3:CD003869
  5. Bradley KA, Mehta . Management of brain metastases. Semin Oncol. 2004;31:693–701
  6. Doolittle ND, Abrey LE, Bleyer WA, Brem S, Davis TP, Dore-Duffy P, et al. New frontiers in translational research in neuro-oncology and the blood–brain barrier: report of the tenth annual blood–brain barrier disruption consortium meeting. Clin Cancer Res. 2005;11:421–428
  7. Gerstner ER, Fine RL. Increased permeability of the blood–brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007;25:2306–2312
  8. Pujol JL, Monnier A, Berille J, Cerrina ML, Douillard JY, Rivière A, et al. Phase II study of nitrosurea fotemustine as single drug chemotherapy in poor prognosis non small cell lung cancer. Br J Cancer. 1994;69:1136–1140
  9. Rivière A, Le Cesne A, Berille J, Baio S, Le Chevalier T. Cisplatin fotemustine combination in inoperable non small cell lung cancer: preliminary report of a French multicenter phase II trial. Eur J Cancer. 1994;30A:587–590
  10. Cotto C, Berille J, Souquet PJ, Riou R, Croisile B, Turjman F, et al. A phase II trial of fotemustine and cisplatin in central nervous system metastases from non small cell lung cancer. Eur J Cancer. 1996;32A:69–71
  11. Robinet G, Thomas P, Breton JL, Léna H, Gouva S, Dabouis G, et al. Results of a Phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francaise de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol. 2001;12:59–67
  12. Lee DH, Han JY, Kim HT, Yoon SJ, Pyo HR, Cho KH, et al. Primary chemotherapy for newly diagnosed non small cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomized pilot study. Cancer. 2008;113:143–149
  13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  14. Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol. 1989;42:703–709
  15. Simon R. Optimal two-stage design for phase II clinical trials. Control Clin Trials. 1989;10:1–10
  16. Langer C, Metha MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005;23:6207–6219
  17. Wong J, Hird A, Kirou-Mauro A, Napolskikh J, Chow E. Quality of life in brain metastases radiation trials: a literature review. Curr Oncol. 2008;15:25–45
  18. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–751
  19. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21:2529–2536
  20. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002;20:3644–3650
  21. Suh JH, Stea B, Nabid A, Kresl JJ, Fortin A, Mercier JP, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol. 2006;24:106–114
  22. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98
  23. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, et al. Phase III randomized tral comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20:4285–4291
  24. Bernardo G, Cuzzoni Q, Strada MR, Bernardo A, Brunetti G, Jedrychowska I, et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest. 2002;20:293–302
  25. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22:1118–1125
  26. Cortot AB, Gerinière L, Robinet G, Breton JL, Corre R, Falchero L, et al. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol. 2006;17:1412–1417
  27. Olson JJ, Paleologos NA, Gaspar LE, Robinson PD, Morris RE, Ammirati M, et al. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol. 2010;96:115–142

PII: S0169-5002(10)00376-4

doi: 10.1016/j.lungcan.2010.07.013

Lung Cancer
Volume 72, Issue 1 , Pages 59-63 , April 2011

Article Tools

* Image Usage & Resolution